Science
31 Oct 2019
Study of a Human Physiologically Based Pharmacokinetic Model for the Plasticiser, Hexamoll® DINCH
Development, Testing, Parameterization, and Calibration of a Human Physiologically Based Pharmacokinetic Model for the Plasticizer, Hexamoll® Diisononyl-Cyclohexane-1, 2-Dicarboxylate Using In Silico, In Vitro, and Human Biomonitoring Data
Introduction
A physiologically based pharmacokinetic model for Hexamoll® diisononyl-cyclohexane-1, 2-dicarboxylate was developed to interpret the biokinetics in humans after single oral doses. The model was parameterized with in vitro and in silico derived parameters and uncertainty and sensitivity analysis was used during the model development process to assess structure, biological plausibility and behavior prior to simulation and analysis of human biological monitoring data...
READ THE FULL STUDY HERE
Authors
Kevin McNally, Craig Sams, George Loizou
Exposure and Health Consequences, Health and Safety Executive, Buxton, United Kingdom
Publication
Submitted to Predictive Toxicology, a section of the journal Frontiers in Pharmacology
Received 2019 May 17; Accepted 2019 Oct 31.